NOX1 and idiopathic pulmonary fibrosis: Notably, the NOX1/NOX4 dual inhibitor GKT137831 is the only NOX inhibitor that has entered clinical trials [GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis (GKT137831), NCT03865927].